On Monday, Sylvie Berrebi was invited to attend the inspiring France Biotech event featuring a thought-provoking ESG round table discussion. 🌍 The discussions on environmental, social, and governance responsibilities were truly insightful, reaffirming the commitment to sustainable practices in Life Sciences. At MEDiSTRAVA our corporate communication team actively supports French biotech companies and their leaders in their pursuit of life science innovations. A big thank you to France Biotech for organising the event! Looking forward to continuing these important conversations and collaborations. #ESG #Sustainability #Biotechnology #FranceBiotech #Networking
MEDiSTRAVA, an Inizio Company’s Post
More Relevant Posts
-
We are spearheading a bold new movement. Together, we can reshape the future of healthcare. https://lnkd.in/dNkzuU6P.
Conscious Change 2030 is our rallying cry. It’s an industry-wide call to action to bring more diverse voices and experiences into positions of influence by the start of the next decade. Join us in making this vision a reality. Your voice matters. Together, we can reshape the future of healthcare. 👉 https://lnkd.in/dNkzuU6P
-
-
Yesterday, the MEDiSTRAVA Strategic Communications team attended the BioIndustry Association (BIA) Summer Party. It was a great evening of networking and discussing the latest innovations in the life sciences sector. We appreciated the opportunity to connect with industry peers, exchange ideas, and explore potential partnerships. Thank you to the BIA for organising such an excellent event. We look forward to future opportunities to engage with this dynamic community. #LifeSciences #BIA #Networking #Innovation #BIAsummerparty
-
-
Congratulations to our client Abingworth, which co-led Myricx Bio’s impressive £90m ($114m) Series A funding round, one of the largest early stage raises ever by a biopharma company in Europe.
FUNDING NEWS: We are thrilled to announce our £90m ($114m) series A financing, one of the largest biotech series A in European biotech and the largest in the UK this year. The round was co-led by new investors Novo Holdings and Abingworth. Additional new investors British Patient Capital, Cancer Research Horizons and Eli Lilly and Company also participated alongside founding investors Brandon Capital and Sofinnova Partners. The series A funds enable us to build out our proprietary N-Myristoyltransferase inhibitor (#NMTi) antibody-drug conjugate (#ADC) payload platform and advance our pipeline of NMTi-ADCs through clinical proof of concept targeting clinically validated tumour-associated antigens. The ADC area is one of the most promising modalities and new payloads are urgently needed. Having been a virtual company since spinning out from Imperial College London and The Francis Crick Institute, we will now move to establish laboratory operations in London’s biotech hub and will be expanding our management and R&D teams. Welcome to our new investors and thank you to everyone that has contributed to the progress of the company so far, not least our founding scientists Ed Tate, Roberto Solari and Andy Bell. Exciting times ahead. Read the full release HERE https://lnkd.in/eSu9mP3c #venturecapital #financing #drugdevelopment #UKbiotech
-
-
Dive into AnaMaria-Corina Afuza's latest article on the Challenges and Innovations in Psychopharmacology Trials. Discover the cutting-edge advancements and the hurdles the industry is overcoming to push the boundaries of mental health treatment. Read now and stay ahead in the field! https://lnkd.in/eBWy5bdH. #Psychopharmacology #ClinicalTrials #Innovation #MedComms #MentalHealth #PharmaInnovation
-
-
We’re looking forward to attending the BioIndustry Association (BIA)’s Summer Party next week, at the Langham Hotel in London. Come and say hello to our team! 👋 Frazer Hall Sandi Greenwood Leila Adlam #BIA #Networking #MedComms
-
-
We at MEDiSTRAVA were honoured to sponsor the Media Commentator Award at this year’s European Mediscience Awards 2024, celebrating outstanding commentary in the life science sector. It was a privilege to host a table including highly regarded and experienced industry journalists, including Melanie Senior from Nature Biotechnology/Evaluate/In Vivo, Ayisha Sharma from Endpoints News, and Amy Brown, who was announced shortly after the event as the new UK anchor for BiotechTV. BiotechTV’s founder and host Brad Loncar was the winner of this year’s Media Commentator Award, and Amy joins the rapidly growing BiotechTV team to bring sector insights from interviews with CEOs from the most exciting emerging biopharma companies in the UK and beyond. We’d like to congratulate Amy on this exciting new role and look forward to seeing her contributions to BiotechTV! #MediscienceAwards #MediaCommentator #BiotechTV
-
-
Many congratulations to Brad Loncar of BiotechTV who won Media Commentator of the Year 2024 at this year’s European Mediscience Awards 2024 dinner, which was held last night in London. As proud sponsor of the Media Commentator Award, we appreciate the importance of highlighting and celebrating those who bring insightful comment and elevate the conversation in our industry. The European Mediscience Awards is the largest annual gathering of the biotech and life sciences community in Europe to recognise company and individual achievements in our industry. Our congratulations go to all the other award winners and to those shortlisted. #MediscienceAwards #MediaCommentator
-
-
#8 on the MM+M Agency 100! Huge thanks to our team & partners. https://lnkd.in/e8m-eZ4s #MMMAgency100 #InizioMedical #HealthcareExcellence #Innovation
We are thrilled to share that we have secured the 8th spot in the prestigious MM+M Agency 100! 🎉 A massive thank you to our incredible team and partners. 👏 This placement reflects our dedication to excellence in medical and healthcare communications. Let's keep innovating and making a difference! 🌟 https://lnkd.in/e8m-eZ4s #MMMAgency100 #InizioMedical #HealthcareExcellence #Innovation
-
-
We are thrilled to announce that our client, Amber Therapeutics, has successfully closed a $100 Million Series A financing round. This significant milestone will propel the development of their groundbreaking Amber-UI Neuromodulation Therapy towards US FDA approval and we're proud to support them on this transformative journey. The news has already garnered attention from leading trade journals, including Endpoints News, FirstWord HealthTech, Fierce Biotech and BioWorld News, highlighting the immense potential and impact of this breakthrough therapy. Read the full press release: https://lnkd.in/ecySTVpg #SeriesAFunding #Neuromodulation #MedicalInnovation
-
